S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Laser breakthrough could send stock soaring 2,467% (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Laser breakthrough could send stock soaring 2,467% (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Laser breakthrough could send stock soaring 2,467% (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
Laser breakthrough could send stock soaring 2,467% (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag

Xeris Biopharma (XERS) Stock Forecast, Price & News

$2.82
+0.20 (+7.63%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.63
$2.82
50-Day Range
$1.27
$2.95
52-Week Range
$0.97
$3.03
Volume
819,559 shs
Average Volume
N/A
Market Capitalization
$382.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Xeris Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
77.3% Upside
$5.00 Price Target
Short Interest
Bearish
6.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.47) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

465th out of 983 stocks

Pharmaceutical Preparations Industry

221st out of 486 stocks


XERS stock logo

About Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Xeris Pharmaceuticals (XERS) Gets a Buy from H.C. Wainwright
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Xeris Biopharma posts record revenue in 1Q
Xeris Biopharma (XERS) Set to Announce Earnings on Tuesday
Xeris Biopharma secures US patent for XeriSol formulations
Q4 2022 Xeris Biopharma Holdings Inc Earnings Call
See More Headlines

XERS Price History

XERS Company Calendar

Last Earnings
3/08/2023
Today
6/04/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XERS
Fax
N/A
Employees
294
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+77.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-94,660,000.00
Pretax Margin
-64.92%

Debt

Sales & Book Value

Annual Sales
$110.25 million
Book Value
$0.22 per share

Miscellaneous

Free Float
129,622,000
Market Cap
$382.19 million
Optionable
Not Optionable
Beta
N/A

Social Links


Key Executives

  • Paul R. EdickPaul R. Edick
    Chairman & Chief Executive Officer
  • John Patrick Shannon
    President & Chief Operating Officer
  • Steven M. Pieper
    Chief Financial Officer
  • Steven Prestrelski
    Chief Scientific Officer
  • Ken Johnson
    Senior VP-Clinical Development & Medical Affairs













XERS Stock - Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XERS shares.
View XERS analyst ratings
or view top-rated stocks.

What is Xeris Biopharma's stock price forecast for 2023?

3 brokerages have issued 1 year price objectives for Xeris Biopharma's stock. Their XERS share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 77.3% from the stock's current price.
View analysts price targets for XERS
or view top-rated stocks among Wall Street analysts.

How have XERS shares performed in 2023?

Xeris Biopharma's stock was trading at $1.33 on January 1st, 2023. Since then, XERS stock has increased by 112.0% and is now trading at $2.82.
View the best growth stocks for 2023 here
.

When is Xeris Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our XERS earnings forecast
.

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) released its earnings results on Wednesday, March, 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.06. The firm earned $33.14 million during the quarter, compared to analyst estimates of $31.04 million. Xeris Biopharma had a negative trailing twelve-month return on equity of 147.04% and a negative net margin of 64.08%.

What ETF holds Xeris Biopharma's stock ?

iShares Neuroscience and Healthcare ETF holds 14,729 shares of XERS stock, representing 0.58% of its portfolio.

What guidance has Xeris Biopharma issued on next quarter's earnings?

Xeris Biopharma updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$165.00 million, compared to the consensus revenue estimate of $146.90 million.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and Organigram (OGI).

When did Xeris Biopharma IPO?

(XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Biopharma's stock symbol?

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (6.38%), BlackRock Inc. (6.21%), Geode Capital Management LLC (1.87%), State Street Corp (1.68%), JPMorgan Chase & Co. (0.57%) and Deltec Asset Management LLC (0.46%). Insiders that own company stock include Paul R Edick and Steven Prestrelski.
View institutional ownership trends
.

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xeris Biopharma's stock price today?

One share of XERS stock can currently be purchased for approximately $2.82.

How much money does Xeris Biopharma make?

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $382.19 million and generates $110.25 million in revenue each year. The company earns $-94,660,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Xeris Biopharma have?

The company employs 294 workers across the globe.

How can I contact Xeris Biopharma?

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for the company is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.

This page (NASDAQ:XERS) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -